The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent …
IM Pedersen, AM Buhl, P Klausen… - Blood, The Journal …, 2002 - ashpublications.org
Antibodies against CD20 can activate complement and induce antibody-dependent cellular
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent …
IM Pedersen, AM Buhl, P Klausen, CH Geisler… - Blood, 2002 - cir.nii.ac.jp
抄録< jats: p> Antibodies against CD20 can activate complement and induce antibody-
dependent cellular cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies …
dependent cellular cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies …
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent …
IM Pedersen, AM Buhl, P Klausen, CH Geisler… - Blood, 2002 - europepmc.org
Antibodies against CD20 can activate complement and induce antibody-dependent cellular
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
[HTML][HTML] The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase …
IM Pedersen, AM Buhl, P Klausen, CH Geisler… - Blood, 2002 - Elsevier
Antibodies against CD20 can activate complement and induce antibody-dependent cellular
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
[PDF][PDF] The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase …
IM Pedersen, AM Buhl, P Klausen, CH Geisler… - BLOOD, 2002 - researchgate.net
B-cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia in the
Western world, with an annual incidence exceeding 5 new cases per 100 000 individuals …
Western world, with an annual incidence exceeding 5 new cases per 100 000 individuals …
[引用][C] The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase …
IM PEDERSEN, AM BUHL, P KLAUSEN… - Blood, 2002 - pascal-francis.inist.fr
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic
leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism CNRS …
leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism CNRS …
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent …
IM Pedersen, AM Buhl, P Klausen, CH Geisler… - …, 2002 - pubmed.ncbi.nlm.nih.gov
Antibodies against CD20 can activate complement and induce antibody-dependent cellular
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
cytotoxicity (ADCC) in B lymphocytes. In B-cell lines, such antibodies also induce apoptosis …
[引用][C] the chimeric anti-CD20 antibody rituximab induces apoptosis in C-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase …
IM PEDERSEN - Blood, 2002 - cir.nii.ac.jp
the chimeric anti-CD20 antibody rituximab induces apoptosis in C-cell chronic lymphocytic
leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism | CiNii …
leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism | CiNii …